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Abstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies 
has substantially inﬂ  uenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). 
Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the 
various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this 
drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance 
treatment. The addition of rituximab to the well established CHOP regimens has increased 
achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted 
worldwide as standard of care. Although conﬂ  icting results are available, rituximab is widely 
used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 
2 studies show a considerable efﬁ  ciency for most of these B-NHL variants. Current research 
focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and 
combination with novel agents.
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Introduction
Monoclonal antibodies as targeted therapies
More than 100 years ago Paul Ehrlich envisioned anti-tumor therapies using mono-
clonal antibodies (Ehrlich P. 1900. Proc Royal Soc London, 66:424–8.) However, it 
took several decades to fulﬁ  l the technical requirements for the implementation of 
this immunotherapy approach in clinical practice. Kohler and Milstein developed the 
hybridoma technique, which enabled large-scale monoclonal antibody production 
(Kohler and Milstein 1975). Early studies demonstrated efﬁ  cacy of antibodies and were 
the basis for the further development of more speciﬁ  c antibodies in non-Hodgkin’s 
lymphoma (NHL) (Nadler et al 1980; Press et al 1987; Maloney et al 1992). With the 
deﬁ  nition of universal tumor antigens suitable for therapeutic targeting, the generation 
of highly active drugs was greatly accelerated.
B-lymphocytes are characterized by a variety of speciﬁ  c surface antigens which 
can serve as speciﬁ  c targets for therapeutic antibodies; however, CD20 early attracted 
special attention. This antigen is expressed uniformly on all benign or malignant 
B-cells, except the very early B-cells and mature plasma cells. Therefore, even elimi-
nation of all CD20 positive cells allows regeneration of a B-cell repertoire from the 
pool of immature B-cells and would facilitate sustained production of the acquired 
immunoglobulin repertoire. The exact function of CD20 is not yet entirely under-
stood. Most probably it is involved in B-cell differentiation and activation, as well 
as regulation of transmembrane calcium conductance (Riley and Sliwkowski 2000). 
Importantly, it is expressed stably and not internalized upon speciﬁ  c binding (Smith 
2003). Additionally, CD20 is not shed, and there is no soluble form of CD20 that 
could interfere with therapeutic antibodies.Biologics: Targets & Therapy 2008:2(4) 620
Hauptrock and Hess
Initially, a murine anti-CD20 antibody Y2B8 was 
developed by BiogenIdec. As murine antibodies are 
associated with a high rate of development of human anti-
mouse antibodies (HAMA), this could result in allergic reac-
tions and reduced efﬁ  cacy of the drug. Therefore the primary 
antibody had been genetically engineered and rituximab is 
now a chimeric IgG1 antibody with only the antigen binding 
site originating from the parental murine antibody.
Interestingly, until now there is no full understanding 
of the precise mechanism of action of this drug. It is 
generally accepted that effector mechanisms of the 
host are needed to fully implement therapeutic efﬁ  cacy. 
Especially antigen dependent cellular toxicity (ADCC) 
seems to play an important role, which is promoted by 
the human Fc portion of the antibody (Clynes et al 2000; 
Stockmeyer et al 2000; Smith 2003). Polymorphisphms 
in the Fc-receptor of the effector cells may contribute to 
the therapeutic efﬁ  cacy (Cartron et al 2002). Additionally, 
complement-dependent cytotoxicity (CDC) and direct 
induction via intracellular signaling are assumed to be 
involved in tumor cell killing.
Preclinical data showed successful depletion of B-cells 
from blood and lymph nodes in macaque monkeys. Upon 
this, the ﬁ  rst clinical trial was performed in patients with 
indolent lymphoma, and rituximab dose was increased up 
to 500 mg/m² (Maloney et al 1994). In a subsequent trial in 
37 patients using 4 doses of rituximab 375 mg/m2, a response 
rate of 46% was noted. These exciting results promoted 
further development of rituximab.
No dose-limiting toxicity has been determined in these 
initial trials and, interestingly, no deﬁ  nite maximum toler-
able dose or a well established optimal dose of this drug 
has been found so far. Hence, 375 mg/m2 has become the 
worldwide accepted rituximab standard dose, at least for 
nodal NHL. Some studies, however, have tested alternative 
dose regimens, showing that increased doses might be more 
efﬁ  cient (O’Brien et al 2001). Initially, rituximab was given 
as a once-weekly regimen, but the combination with standard 
chemotherapy regimens is now usually applied in the rhythm 
of chemotherapy cycles, although no pharmacokinetic data 
exist. Recent data suggest that pharmacokinetically based 
timing might improve efﬁ  cacy in aggressive lymphoma; 
however, additional information is required on this and 
other entities to establish such a concept (Pfreundschuh 
et al 2007).
The antibody is given over 4 hours as a continuous 
infusion with incremental application of the drug. Recent 
trials have shown that an application within one hour might 
be safely possible as well, and this could further increase the 
convenience of use (Ghielmini et al 2005b).
The side effect proﬁ  le of rituximab is well known. 
Especially during the first application symptoms like 
fever, chills, and rigors can occur which in general can be 
terminated by symptomatic treatment with steroids or anti-
histaminic drugs or lowering of the infusion rate. As these 
side effects are more common in patients with high tumor 
load or a high number of circulating tumor cells, an overlap 
with tumor lysis syndrome can be assumed (Jensen et al 
1998; Yang et al 1999). However, side effects are usually 
less prominent during the subsequent treatment cycles and 
only sporadically are patients unable to tolerate further 
rituximab treatment. Additional side effects are rash, 
nausea and vomiting, headache, or myalgias, but these are 
usually grade I or II. Speciﬁ  c precautions should be taken 
in patients prone to viral infections or reactivations, such as 
those with hepatitis B infection, where fulminant hepatitis 
cases have been observed (Tsutsumi et al 2005; Aksoy 
et al 2006; Ozgonenel et al 2006; Perceau et al 2006). The 
occurrence of cases of leucoencephalopathy upon treatment 
with rituximab-containing regimens has been alarming, 
and although their frequency was low these events should 
be watched carefully (Goldberg et al 2002; Matteucci 
et al 2002). HAMA are observed with low frequency and 
their biological meaning remains undetermined. Overall, 
most studies have shown that the addition of rituximab to 
various chemotherapy regimens in general contributes only 
little to the speciﬁ  c toxicity, regardless of whether low- or 
high-intensity regimens are used. Especially hematopoietic 
recovery and rate of infections do not seem to be altered 
(Coifﬁ  er et al 2002; Hiddemann et al 2005).
The application of rituximab leads to a depletion of 
peripheral B-cells and recovery is not noted until 6 months 
after treatment termination. Initially, potential increase of 
infection rates during short-term and long-term follow up 
caused severe concern. But a surprisingly low infection 
rate has been noted so far, even if long-term maintenance 
therapy is applied (Ghielmini et al 2005a). However, there 
are reports of rituximab-associated neutropenia, which 
can be protracted, and with higher rituximab doses infec-
tion rates might increase (Pfreundschuh et al 2007). Only 
long-term follow up will show if more secondary infections 
or secondary tumors are diagnosed with several years of 
continuous B-cell depletion.
The ﬁ  rst trials were performed in indolent lymphoma, 
but rituximab has now been broadly evaluated in almost 
every sub-entity of NHL. This review will focus on the main Biologics: Targets & Therapy 2008:2(4) 621
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established indications for rituximab and also include a brief 
overview of current data in rare lymphoma entities.
Activity in deﬁ  ned lymphoma 
entities
Follicular lymphoma (FL)
Follicular lymphoma is the most common subtype of indolent 
NHL, representing about 25% of all B-NHL and character-
ized by a heterogeneous clinical course. Frequently, tumors 
grow slowly and a substantial proportion of patients can be 
observed for a long period without needing any therapy. 
Eventually, however, patients develop rapid enlargement 
of nodes, compression symptoms, or bone marrow insuf-
ﬁ  ciency, and treatment has to be initiated. Until now, no 
curative treatment besides allogeneic transplantation could 
be established, and with sufﬁ  cient follow up almost all 
patients relapse. Although the disease is susceptible to further 
treatments, a resistance to conventional cytotoxic drugs can 
develop during the disease course and hamper further effec-
tive treatment. Because of its generally slow progression rate 
FL was accepted as an ideal disease for the development of 
rituximab, and the ﬁ  rst clinical phase I/II trials of single-
agent rituximab were conducted with indolent lymphomas 
(Maloney et al 1994). As described above, treatment was well 
tolerated and the dose of 375 mg/m2 for the 4-dose weekly 
schedule was established.
The pivotal phase II trial tested rituximab monotherapy 
in refractory or relapsed FL in 166 patients. The overall 
response rate (ORR) was 48% with a complete response 
(CR) rate of 10%. The median time to progression (TTP) 
reached 11.6 months (McLaughlin et al 1998; Colombat 
et al 2006). These encouraging results led to the approval 
of rituximab by the US Food and Drug Administration in 
1997. Recently an update of this trial has been published in 
which an overall best response rate of 74% was described, 
with 50% of patients achieving CR. Median progression-free 
survival (PFS) was 23.5 months. Interestingly, long-term 
remissions have been noted in 24% of patients, who had not 
relapsed after 5 years. However, as this rate further decreased 
during follow up, a curative potential at least in a subset of 
patients cannot be assumed (Colombat et al 2006). Similar 
data for single-agent rituximab from 185 patients with newly 
diagnosed or refractory FL was shown by the Swiss Group 
for Clinical Cancer Research (SAKK) (Ghielmini et al 
2004). The ORR was 67% in chemotherapy-naïve patients 
and 46% in pre-treated patients. Previous chemotherapy 
and bulky disease were identiﬁ  ed as independent negative 
predictors for clinical response.
One of the ﬁ  rst studies investigating rituximab monotherapy 
in untreated follicular lymphoma was published in 2001, 
showing an ORR of 73% and a CR of 26%. However, TTP was 
the same as in the control group of “watch and wait” patients 
(2 years) (Colombat et al 2001).
To further improve the efﬁ  cacy of single-agent rituximab 
via stimulation of the host defence system, the combination 
of single-agent rituximab with the application of granulocyte-
macrophage colony-stimulating factor (GM-CSF) has 
been evaluated. In a recently published phase II study in 
33 relapsed patients, an ORR of 70%, a CR (with CRu 
[complete remission unconfirmed]) rate of 45%, and a 
median PFS of 16.5 months (Cartron et al 2008) were noted, 
which compares favorably with the historic data and merits 
further evaluation. Other studies analyzed the possibility of 
re-treating patients in relapse who initially responded to ritux-
imab monotherapy (Davis et al 2000; Lemieux et al 2004; 
Ghielmini et al 2004b). The response rates were comparable 
with those of the initial treatment. Surprisingly, median 
TTP was longer after the rituximab re-treatment than after 
the previous therapy. It can be speculated that rituximab is 
associated with a kind of vaccination effect, which can be 
boosted by subsequent infusions.
From clinical praxis and experience with other tumor 
entities as well as NHL it is accepted that combination 
therapies frequently demonstrate a super-additive efﬁ  cacy 
of single agents. As additional in vitro analyses demon-
strated an additive effect of the combination of rituximab 
with chemotherapy, combinations of cytotoxic agents with 
the monoclonal antibody were subsequently evaluated. In 
untreated patients, Czuczman et al were the ﬁ  rst to report 
on the combination of rituximab with the well established 
CHOP-regimen (R-CHOP: rituximab, cyclophosphamide, 
doxorubicin, vincristine, prednisone) in a phase II trial. 
An ORR of 100% (87% CR or CRu) was demonstrated 
(Czuczman 1999). The data of 9 years of follow up showed 
that after this period almost 50% of patients were progression 
free (Czuczman et al 2004). Median TTP was 82 months. 
Other examples of an impressive therapeutic efﬁ  cacy came 
from trials evaluating, for instance, the combination with 
ﬂ  udarabine-based regimens or bendamustine. For example, 
a multicenter study with 63 patients with relapsed follicular 
lymphoma or mantle cell lymphoma evaluated the combi-
nation of rituximab with bendamustine. The ORR was 90% 
with a 60% CR rate. The median time of PFS was 24 months 
(Zinzani et al 2004; Rummel et al 2005).
With the availability of the phase II data, a series of large 
phase III studies was initiated to prove the value of rituximab Biologics: Targets & Therapy 2008:2(4) 622
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in addition to standard treatments. The trial of the German 
Low Grade Lymphoma Study Group (GLSG) compared the 
combination of R-CHOP with CHOP chemotherapy alone 
(Hiddemann et al 2005). ORRs were similar, but median TTP 
was signiﬁ  cantly reduced in the CHOP arm (2.6 years). In 
the R-CHOP arm, median TTP was not reached after 3 years 
of observation. Furthermore, despite the short follow-up 
time, OS was signiﬁ  cantly longer in patients who received 
R-CHOP. However, the inclusion of consolidation high-dose 
therapy for a substantial proportion of patients does not allow 
direct comparison with the below-mentioned trials. The East 
German Study Group Hematology and Oncology (OSHO) 
randomized patients with low grade B-NHL to a therapy 
with MCP (mitoxantrone, chlorambucile, prednisone) vs 
the combination of R-MCP (Herold et al 2007). The results 
showed an advantage in response rates (ORR 92% vs 75%, 
CR 50% vs 25%) and in median event-free survival (EFS) 
and PFS (EFS after 47 months: not reached vs 26 months; 
PFS not reached vs 28.8 months) for patients treated with 
R-MCP. Four-year OS was significantly increased for 
patients receiving R-MCP (87% vs 74%, p = 0.0096). 
A similar beneﬁ  t of chemoimmunotherapy was demon-
strated in the trial of Marcus et al (2005) comparing R-CVP 
with CVP (cyclophosphamide, vincristine, prednisone). An 
update of this trial with a median follow up of 53 months 
showed a signiﬁ  cantly prolonged median TTP (34 months 
vs 15 months) and OS (81% vs 71%; p = 0.03) for patients 
in the R-CVP group (Marcus et al 2006). In another trial, the 
impact of rituximab addition to the combination of CHVP 
(cyclophosphamide, doxorubicin, teniposide, prednisone) 
plus interferon was analyzed (Salles et al 2004). CR rates 
were higher in the R-CHVP-interferon arm (75% vs 59%) and 
for a follow up of 5 years there was a statistically signiﬁ  cant 
advantage in EFS (53% vs 37%) but not in OS (84% vs 79%) 
for R-CHVP-interferon compared with CHVP-interferon 
was reported. A signiﬁ  cant OS beneﬁ  t was noted only for 
patients with high-risk features according to the FLIPI score 
(Salles et al 2007).
Although the efficacy of the addition of rituximab 
has been demonstrated for untreated patients, additional 
randomized phase-III-trials focussed on patients with 
relapsed disease. The European Organisation for Research 
and Treatment of Cancer (EORTC) compared CHOP vs 
R-CHOP and showed a signiﬁ  cantly better ORR (85 vs 72%) 
and PFS (33.1 vs 20.2 months) in the R-CHOP arm (van Oers 
et al 2006). When rituximab was added to the FCM-schedule 
(fludarabine, cyclophosphamide, mitoxantrone), ORR, 
PFS, and OS were increased (79 vs 58%; 3-year PFS not 
reached vs 21 months; estimated 2-year OS: 90 vs 70%, NS) 
(Forstpointner et al 2006). As these studies were started 
in parallel with ﬁ  rst-line trials, a substantial proportion of 
patients had not been treated with prior rituximab, and a trial 
including only patients with rituximab pre-treatment has not 
been performed. Owing to the repeated efﬁ  cacy of single-
agent rituximab and the well balanced characteristics of the 
various phase III trials, it can be assumed that rituximab is 
established as a key component of combined chemoimmu-
notherapy protocols for ﬁ  rst- and second-line therapy.
Although the introduction of rituximab has not led to the 
development of curative treatments, it has markedly prolonged 
PFS and OS of patients with follicular lymphoma so that 
many patients ultimately die of other reasons than lymphoma. 
With this success and the beneﬁ  cial safety proﬁ  le, long-
term application (maintenance) to prolong the disease free 
interval has been considered an interesting option. Various 
maintenance regimens have been tested, from 1 dose every 
2 months up to 4 doses every 3 months, which all proved to 
be feasible and have a remarkably low rate of side effects. 
Randomized studies investigated the signiﬁ  cance of rituximab 
maintenance therapy after a successful induction therapy. 
The SAKK randomized untreated and relapsed patients with 
follicular lymphoma who had at least reached stable disease 
after a rituximab containing induction between 4 additional 
rituximab infusions every 8 weeks or no further treatment 
(Ghielmini et al 2004). Patients receiving rituximab mainte-
nance had an advantage for EFS (23 months vs 12 months). 
The highest beneﬁ  t was observed in previously untreated 
patients. Another trial compared rituximab maintenance 
therapy in patients initially responding to rituximab with 
starting the antibody after lymphoma progression (Hainsworth 
et al 2005). EFS was longer in the group of rituximab main-
tenance (31.3 months vs 7.4 months). However, duration of 
the rituximab beneﬁ  t was similar in the maintenance and the 
re-treatment group (31.3 months vs 27.4 months), and there 
was no difference in time to chemotherapy after stopping 
rituximab. The above-mentioned EORTC trial (van Oers et al 
2006) demonstrated a signiﬁ  cantly improved PFS and OS for 
relapsed patients with a rituximab maintenance after CHOP 
or R-CHOP therapy. After the results of this trial rituximab 
was approved for maintenance therapy in patients with 
relapsed follicular lymphoma (van Oers et al 2006). Similar 
results in relapsed patients were reported by the GLSG for a 
rituximab maintenance after R-FCM chemoimmunotherapy 
(Forstpointner et al 2006).
Whereas maintenance therapy can be considered to be 
established for patients with relapsed disease, the value of Biologics: Targets & Therapy 2008:2(4) 623
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maintenance treatment for patients undergoing ﬁ  rst-line 
treatment is being investigated in several trials. The PRIMA 
trial compares randomly maintenance therapy (1 dose, every 
3 months, for 2 years) vs no further treatment for patients 
with chemoimmunotherapy. Furthermore, the next study of 
the GLSG will evaluate maintenance treatment in the context 
of high-dose consolidation treatment.
Aggressive lymphoma
The ﬁ  rst phase II trial using rituximab monotherapy in 
relapsing or refractory patients with diffuse large B-cell 
lymphoma (DLBCL) was published in 1998 (Coifﬁ  er et al 
1998). ORR was 37% and PFS reached 8 months. In spite 
of this promising single-agent activity, combination thera-
pies rapidly became the focus of interest, and single-agent 
rituximab is today used only in palliative settings. Several 
phase II trials demonstrated high and long-lasting remission 
rates by combining rituximab with chemotherapy in the ﬁ  rst-
line treatment of patients with aggressive lymphoma. Vose 
et al (2001) showed that the addition of rituximab to CHOP 
chemotherapy resulted in an ORR of 89% with 56% CR after 
6 cycles of this regimen.
Subsequently, randomized phase III trials demonstrated 
the superiority of the addition of rituximab to CHOP or 
CHOP-like chemotherapy against CHOP chemotherapy 
alone. The trial of the French GELA study group (Groupe 
d’Etudes des Lymphomes de l’Adulte) comparing 8 cycles 
R-CHOP with CHOP in elderly patients with DLBCL 
(Coifﬁ  er et al 2002) resulted in a signiﬁ  cant survival beneﬁ  t 
for patients in the R-CHOP arm (OS 3.1 years vs not reached 
after 5 years, p = 0.007). CR rates were 76% in the R-CHOP 
arm compared with 63% in the CHOP arm, and EFS was 
3.8 years (R-CHOP) vs 1.1 years (CHOP). This beneﬁ  t was 
present in patients with low- or high-risk features as deter-
mined by the International Prognostic Index (IPI). Initially 
it was assumed that the bcl-2 status inﬂ  uences treatment 
results, although this is still under debate (Mounier et al 
2003, 2006). This study was path breaking in the approval of 
the combination of rituximab to chemotherapy for ﬁ  rst line 
treatment. In another trial of elderly patients with aggres-
sive lymphoma, a comparison of CHOP-14 to R-CHOP-14 
(RICOVER-60-trial) was carried out (Pfreundschuh et al 
2008b). The authors reported a beneﬁ  t of R-CHOP-14 for 
PFS and OS. Giving 8 instead of 6 cycles of R-CHOP-14 did 
not improve the outcome. The results of these trials suggest 
that at present R-CHOP is the standard ﬁ  rst-line treatment for 
elderly patients with aggressive lymphoma. The results of the 
GELA-trial could be conﬁ  rmed by the MInT study (Mabthera 
International Trial) for younger patients with low-risk 
DLBCL receiving CHOP-like chemotherapy (Pfreundschuh 
et al 2006). Patients in the rituximab combination arm had 
an increased 3-year EFS (79% vs 59%, p   0.0001) and OS 
(93% vs 84%, p = 0.0001). In a recently published follow-
up of the MinT trial (Pfreundschuh et al 2008a) the impact 
of bulky disease measured by the maximum tumor diameter 
(MTD) towards the outcome of R-CHOP was analyzed. 
MTD had an adverse prognostic effect on EFS and OS with 
increased linearity. Adding rituximab to CHOP decreased, 
but did not eliminate, this adverse prognostic effect. In the 
very aggressive B-NHL variants like Burkitt’s lymphoma and 
B-ALL, small trials suggest a beneﬁ  cial effect of rituximab 
in these entities, too (Thomas et al 2006).
Ongoing trials in previously untreated patients focus 
on the comparison of R-CHOP-14 with R-CHOP-21, dose 
escalation studies with protocols like MegaCHOEP, or the 
addition of other active drugs, such as those recently reported 
on the combination of epratuzumab with R-CHOP (Micallef 
et al 2008).
Despite the advanced outcomes in first line treat-
ment, up to 50% of patients relapse after standard 
chemoimmunotherapy, especially if they belong to the 
high risk population based on IPI (Coifﬁ  er 2005). Work 
is ongoing to establish biological risk markers to iden-
tify those patients already early and to optimize ﬁ  rst-line 
treatment. However, for younger patients with relapsed or 
refractory disease, a salvage therapy followed by high-dose 
therapy with autologous stem cell transplantation is cur-
rently standard of care (Philip et al 1995). Using rituximab 
for in vivo purging before stem cell apheresis did not alter 
stem cell mobilization and therefore was rapidly considered 
as standard of care (Magni et al 2000; Flohr et al 2002). 
The addition of rituximab to DHAP (dexamethasone, 
cytarabinoside, cisplatin) salvage chemotherapy was 
compared with a historical control cohort of patients that 
received only DHAP (Sieniawski et al 2007). Response rates 
were higher in the R-DHAP group (63% vs 42%). PFS at 
2 years was 57% with R-DHAP and 18% with DHAP, and 
also OS was better in the R-DHAP group (77% vs 37%). 
Kewalramani et al (2004) showed that adding rituximab to 
ICE (ifosfamide, carboplatin, etoposide) salvage therapy 
improved CR rates compared with historical control patients 
only receiving ICE (53% vs 27%). PFS was marginally better 
in patients who underwent transplantation after R-ICE (54% 
vs 43% after 2 years). Another trial to deﬁ  ne the role of ritux-
imab in salvage and high-dose therapy compared patients 
treated with rituximab in combination with DexaBEAM Biologics: Targets & Therapy 2008:2(4) 624
Hauptrock and Hess
(Dexamethason, BCNU, etoposide, cytarabinoside, 
melphalan) salvage and with BEAM or TBI/Cy conditioning 
therapy to a historical control group without rituximab (Hess 
et al 2006). The OS after 4.5 years in the rituximab group 
was improved only in patients with aggressive lymphoma 
(67% vs 45%), but not in patients with indolent lymphoma. 
These studies suggest that patients receiving salvage 
chemotherapy have a beneﬁ  t when rituximab is added to 
chemotherapy. Although randomized trials have not been 
and probably never will be perfored on this issue, the use 
of rituximab is generally accepted. To deﬁ  ne the optimal 
salvage regimen, the CORAL study (Collaborative trial 
in Relapsed Aggressive Lymphoma) randomized relapsed 
patients between R-ICE and R-DHAP salvage therapy 
prior to autologous stem cell transplantation (Gisselbrecht 
et al 2007). Although in an interim analysis high response 
rates have been reported in this study, patients who were 
initially exposed to rituximab were more difﬁ  cult to salvage 
with the rituximab-containing salvage regimens. The trial 
is also investigating the role of rituximab maintenance 
after autologous stem cell transplantation, but results are 
still outstanding. A recently published Italian randomized 
Table 1 Key studies of rituximab in indolent and aggressive non-Hodgkin’s lymphoma
Author Phase Regimen Patients Results
Indolent lymphoma (follicular lymphoma, single agent)
Maloney et al 
1994
I 375/m² x 4 34, pre-treated ORR: 50%
McLaughlin et al 
1998
II/III 375/m² x 4 166, pre-treated ORR: 48% med. PFS 9 mo
Indolent lymphoma (follicular lymphoma. combination therapies
Czuczman 1999; 
Czuczman et al 
2004
II R-CHOP x 6 38, naïve and pretreated ORR: 100%
CR: 58%
Med. PFS: 9 y+
Hiddemann et al 
2005
III R-CHOP vs CHOP 394, naïve ORR: 96% vs 90% (p = 0.01);
est. 2 y OS: 95% vs 90% 
(p = 0.016)




359, naïve ORR 92% (CR 50%) vs ORR 
75% (CR 25%)
PFS at 47 mo: n.r. vs 28.8 mo;
4 y OS: 87% vs 74% 
(p = 0.0096)
Salles et al 2007 III R-MCP vs MCP 358, naïve CR: 75% vs 59%;
EFS at 5 y: 53% vs 37%;
OS: 84% vs 79% (n.s.)
Marcus et al 
2005, 2006
III R-CVP vs CVP 321, naïve ORR 81% (CR 41%) vs ORR 
57% (CR 10%)
PFS: 34 vs 15 mo; 53 mo;
OS : 81% vs 71% (p = 0.03.
Aggressive lymphoma (DLBCL, single agent)
Coifﬁ  er et al 
1998
II R × 8 30* ORR: 37%
Aggressive lymphoma (DLBCL, combination therapies)
Coifﬁ  er et al 
2002
III R-CHOP vs CHOP 399 Med. EFS: 3.8 y vs 1.1 y;





823 Est. 2 y PFS: 76% vs 60%;
2 y OS: 94% vs 90%
Abbreviations: n.r. not reached; mo, months; y, year; n.s. not signiﬁ  cant; CR, complete respones; ORR, overall survival rate; PFS, progress-free survival.Biologics: Targets & Therapy 2008:2(4) 625
Rituximab in NHL
multicenter trial (Tarella et al 2008) reported on the addition 
of rituximab to high-dose sequential (HDS) chemotherapy 
regimen followed by autologous stem cell transplantation. 
The beneﬁ  t of rituximab to OS was evident in patients 
receiving HDS as salvage therapy (64% with R-HDS vs 
38% with HDS).
The effect of rituximab maintenance after CHOP or 
R-CHOP therapy was analyzed by Habermann et al (2006). 
Only patients treated with CHOP, but not with R-CHOP, in 
ﬁ  rst-line therapy had an improved failure-free survival when 
receiving rituximab maintenance. However, the results of 
this study must be observed critically because the rituximab 
dose during the induction therapy was lower than the standard 
schedule dose (rituximab was added only on cycles 1, 3, 5, 
and 7). Results of the CORAL trial will help to judge the 
value of maintenance therapy in aggressive lymphoma.
Rituximab is now an essential element of currently 
applied ﬁ  rst-line and relapse therapies. Studies evaluating 
dose modiﬁ  cation and maintenance therapies are awaited 
and might expand the current use.
Mantle cell lymphoma (MCL)
Although initially termed as of intermediate aggressiveness 
within the Kiel-classiﬁ  cation, it has by now become clear 
that MCL is associated with the poorest prognosis of all 
peripheral B-cell-lymphoma entities. Single-agent activity of 
rituximab is limited in this disease. In a trial with 88 patients 
an ORR of 27% with only 2.3% CR was reached and the 
duration of remission was short (6–12 months) (Ghielmini 
et al 2005a).
To evaluate the combination of rituximab with chemother-
apy in ﬁ  rst-line therapy, the GLSG conducted a randomized 
trial comparing R-CHOP and CHOP in ﬁ  rst-line treatment 
of 122 MCL patients (Lenz et al 2005). The ORR was bet-
ter in the rituximab arm (94% vs 75%, p = 0.0054) with a 
clearly superior CR rate (34% vs 7%, p = 0.00024). Median 
time to treatment failure was signiﬁ  cantly longer in patients 
receiving rituximab (21 vs 14 months), but there was no dif-
ference in PFS and OS. The efﬁ  ciency of a combination of 
FC (ﬂ  udarabine, cyclophosphamide) with rituximab (R-FC) 
was analyzed in a randomized British trial (Rule et al 2005). 
ORR was 93% in the R-FC and the FC arm and CR rate was 
similar, too (44% R-FC vs 40% FC). There was also no dif-
ference in PFS and OS when rituximab was added. By using 
a combination of rituximab with the intensive chemotherapy 
regimen hyper-CVAD (3 cycles high dose metothrexate and 
cytarabinoside alternating with 3 cycles cyclophosphamide, 
vincristine, doxorubicin, and dexamethasone), a longer PFS 
of 64% after 3 years was reached (Romaguera et al 2005). 
ORR was 97% with a CR rate of  87%. However, this regimen 
was accompanied with a high rate of therapy associated 
mortality (5%) and cases of MDS and acute leukaemia (4%). 
Recently, an OSHO trial failed to demonstrate a beneﬁ  t for 
the combination of rituximab with MCP in comparison with 
MCP; however, in this trial only a limited patient number 
with MCL was included.
The GLSG examined the addition of rituximab to a 
polychemotherapy with FCM (ﬂ  udarabine, cyclophospha-
mide, mitoxantrone) in relapsed and refractory MCL in 
a randomized trial (Forstpointner et al 2004). The results 
demonstrated an improved ORR in MCL patients in the 
rituximab arm (58% vs 46%), but a low CR rate (13% vs 0%). 
PFS and OS were prolonged in the R-FCM group (PFS 
8 months vs 4 months, OS 65% vs 35% after 2 years, 
p = 0.01).
The inﬂ  uence of rituximab in amelioratin the outcome 
after autologous stem cell transplantation was examined in 
a retrospective analysis of Hoerr et al (2004). When ritux-
imab was added to the salvage chemotherapy, a signiﬁ  cant 
beneﬁ  t in PFS and OS was observed in this study. Another 
study analyzed the impact of rituximab in conditioning 
therapy before autologous stem cell transplantation (Dreger 
et al 2007). Adding rituximab to total body irradiation and 
cyclophosphamide (TBI/Cy) did not alter engraftment but 
led to an improved EFS (not reached vs 43 months) and 
OS (87% vs 77% after 4 years) compared with a historical 
control group.
Because duration of MCL remission is frequently short 
especially in relapsed disease, maintenance therapy has been 
investigated in a GLSG trial. After the initial randomiza-
tion to R-FCM vs FCM (Forstpointner et al 2006) a second 
randomization for rituximab maintenance with 4 doses given 
after 3 and 9 months was introduced. PFS was 19 months in 
the observation group and not reached in patients receiving 
the maintenance therapy after 3 years, suggesting a beneﬁ  t 
of rituximab maintenance in MCL patients.
In summary, rituximab is now widely used in MCL 
therapy, although beneﬁ  ts are not as impressive as in other 
lymphoma entities and further additional therapeutic options 
are needed in this disease entity.
Chronic lymphocytic leukemia (CLL) 
and small lymphocytic lymphoma
CLL is characterized by the accumulation of a monoclonal 
population of mature B-cells, resulting in peripheral lym-
phocytosis, bone marrow failure, lymphadenopathy, and Biologics: Targets & Therapy 2008:2(4) 626
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splenomegaly. Although some patients experience prolonged 
phases of stable disease and do not require treatment for a 
long time, others rapidly progress and subsequently experi-
ence poor responses to standard treatment, eg, chlorambucile- 
and ﬂ  udarabine-based therapies. Monoclonal antibodies 
are attractive for these patients and have been evaluated in 
various trials (Table 2). However, in CLL, CD20 is expressed 
to a lesser extent than in normal B-cells or other B-NHL 
and, furthermore, soluble CD20 may hamper the efﬁ  cacy 
of rituximab. In fact, initial results of standard single-agent 
treatment in relapsed disease were disappointing. Trials using 
standard 375 mg/m² rituximab dosing showed response rates 
between 0% and 25% (McLaughlin et al 1998; Huhn et al 
2001; O’Brien et al 2001). There were improved responses 
with increased doses of rituximab of up to 2250 mg/m2 
which resulted in response rates of 75% or a dose-intensive 
rituximab schedule (375 g/m2   3/weekly, for 4 weeks) 
resulting in a response rate of 45% (3% CR) (Byrd et al 
2001). In a ﬁ  rst-line trial, treatment with the monoclonal 
antibody for 4 cycles every 6 months for up to 2 years gave 
a 58% rate (9% CR) (Hainsworth et al 2003). However, 
these results did not translate into clinical praxis. In contrast, 
combination therapy with ﬂ  udarabine-based regimens in 
relapsed disease and ﬁ  rst line therapy gave surprisingly good 
results and hopefully can be conﬁ  rmed in additional trials 
(Keating et al 2005; Wierda et al 2005). For example, in 
relapsed disease, in 177 patients FCR (ﬂ  udarabine, cyclo-
phosphamide, rituximab) resulted in a CR in 25% of patients, 
a nodular PR in 16%, and PR in 32% of patients for an ORR 
of 73%, an outcome that has never been achieved with other 
treatments. The trial testing FCR in untreated patients has 
recently been updated (Tam et al 2008). At median fol-
low up of 6 years, in 300 patients the ORR was 95% and 
72% achieved a CR. 6y-PFS and OS were 51% and 77% 
and median time to progression was 80 months. Although 
patient selection seemed favorable in this trial, the initial 
results of combined modality treatment stimulated a random-
ized study of the German CLL study group comparing FC 
with FC-R in patients with untreated CLL requiring treat-
ment (CLL 8). The accrual of the trial closed in 2007, and 
ﬁ  rst results are expected at the end of this year. As there is 
evidence of synergistic efﬁ  cacy of nucleoside analogues and 
rituximab besides the predominantly used ﬂ  udarabine based 
regimes, other combination therapies were evaluated. The 
combination of cladribine with rituximab with or without 
additional cyclophosphamid resulted in an ORR of 67%–78% 
in heavily pre-treated patients (Robak et al 2007). Finally, 
pentostatin, cyclophosphamide, and rituximab were tested as 
an alternative combination in untreated patients with CLL. 
In 65 patients an ORR of 91% could be achieved (41% CR) 
Table 2 Key studies of rituximab in chronic lymphocytic leukemia and SLL
Autor Phase Regimen Patients Results
Single-agent rituximab
McLaughlin et al 
1998
I/II 375/m²   4 30, pre-treated ORR: 13%, PFS n.a.
Byrd et al 2001 II 375/m²   3 weekly 
for 4 weeks, rep. every 
6 mo
33 relapsed ORR: 45% med. PFS 
10 mo.
O’Brien et al 
2001
II 375–2250/m² 8 (at 2250 mg/m²), 
relapsed
ORR: 75%
Hainsworth et al 
2003
II 375/m² 44 untreated ORR 51%, CR 4%, med. 
PFS 19 months
Combination therapies
Wierda et al 
2005
II FCR 177 relapsed ORR 73%, CR 25%; med. 
PFS 28 mo,
Robak et al 
2007
II 2-CDA, R, ± Cyclo 46 relapsed ORR 74%, med. PFS 
12 mo
Keating et al 
2005; Tam et al 
2008
II FCR 300 untreated ORR: 95%, 72% med. 
PFS 80 mo
Kay et al 2007 II Pentostatin, Cylo, R 64 untreated ORR 91%, CR 41%, med. 
PFS 33 mo
Abbreviations: n.a. not applicable/available; mo, months; y, year; n.s. not signiﬁ  cant; R, rituximab; Cyclo, cyclophosphamide; 2-CDA, cladribine; FCR, ﬂ  udarabine, cyclophosphamide, 
rituximab; CR, complete response; ORR, overall survival rate; PFS, progress-free survival.Biologics: Targets & Therapy 2008:2(4) 627
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(Kay et al 2007), with all precautions in the comparison of 
phase II data; however, median PFS was shorter (33 months) 
compared with FCR. In summary, the nucleoside analogues 
in combination with rituximab appear to be highly efﬁ  cacious 
for the treatment of CLL. It can be speculated, from published 
data and with the availability of presumably positive data 
from the CLL 8 trial, that rituximab will be approved as a 
standard component of CLL treatment.
HIV-associated NHL
Highly active anti-retroviral therapy has led to improved 
survival of patients with HIV infections. NHLs, mainly the 
aggressive variants, have now evolved into one of the most 
common malignancies in these patients. Due to the severe 
immunosuppression, patients initially were precluded from 
treatment with rituximab-containing regimens. However, 
as lymphoma-speciﬁ  c prognosis of these patients is inferior 
to that of non-HIV positive patients, a separate evalua-
tion of the beneﬁ  ts of monoclonal antibody treatment was 
initiated. First trials showed promising response rates with 
the addition of rituximab (Boue et al 2006), but a random-
ized phase III trial showed conﬂ  icting results (Kaplan et al 
2005). A superior ORR for R-CHOP compared with CHOP 
was noted (57.6 vs 47%) but there was no OS beneﬁ  t, as a 
higher treatment-related mortality was observed (14% vs 
2%). For daily praxis, individual decision making should be 
considered, where immune status, performance status, pre-
existing infections, and the lymphoma speciﬁ  c risk should be 
taken into account (Sparano 2007). A consequent antibiotic 
co-treatment and the use of growth factors seem advisable 
(Mounier et al 2007).
Post-transplantation lymphoproliferative 
disorders (PTLD)
PTLD can occur in patients after solid-organ or stem 
cell transplantation with a high incidence (Leonard et al 
2003). PTLD is mostly of B-cell origin, associated with 
EBV infection or reactivation, and features characteristics 
of aggressive lymphoma with rapid disease course and 
involvement of atypical sites. Tapering of immunosuppres-
sion and chemotherapy have been widely used, with mixed 
responses, high relapse rates and, in the latter case, high 
treatment-associated mortality (Leonard et al 2004). Early 
retrospective analyses evaluating single-agent rituximab 
gave variable results, with response rates from 20% to 100% 
(Benkerrou et al 1998; Choquet et al 2006). In a prospective 
multicenter phase II trial in 46 patients with PTLD after solid 
organ transplantation, patients received 4-weekly infusion of 
rituximab. In 43 evaluable patients the ORR was 44%, and 
remissions were sustained for 1 year in 68% of responders. 
OS for the entire cohort was 67% at 1 year (Choquet et al 
2006). As median PFS was 6 months in another trial including 
60 patients (Choquet et al 2007), efforts are made to fully 
explore the efﬁ  cacy of rituximab in combination therapies 
for PTLD. In conclusion, rituximab is a rational choice for 
patients with this difﬁ  cult disease, but may not be sufﬁ  cient as 
single-agent treatment if patients have high-risk features.
Other lymphoma entities
Marginal zone lymphoma (MZL)
MZL accounts for approximately 8%–12% of all NHL and 
comprises 3 related subtypes with distinct biological features 
and clinical characteristics. Extranodal MZLs (MALT) are 
distinguished from nodal MZL and splenic MZL. All sub-
types arise from B-cells that have undergone post-follicular 
differentiation, in the context of chronic antigenic stimula-
tion such as auto-immune mechanisms or chronic infection. 
Whereas nodal MZL are frequently treated in similarly to 
other indolent entities, extranodal and splenic marginal zone 
lymphoma are examined differently.
Extranodal MZL
These lymphomas usually arise in various extranodal sites 
such as conjunctive, stomach, salivary glands, and many 
others. They are characterized by an indolent disease course 
and a slow dissemination rate, and are associated with a 
good prognosis.
The most frequent subtype is gastric MZL, which 
frequently occurs in the context of chronic Heliobacter 
pylori infection (Wotherspoon et al 1991). Forty percent of 
gastric MZL are of indolent, whereas 60% are of aggressive 
histology, and the latter are frequently diagnosed as diffuse 
large cell lymphomas. In case of indolent characteristics asso-
ciated with H. pylori infection, eradication can lead to resolu-
tion of the disease (Wotherspoon et al 1991), whereas patients 
experiencing relapse upon this treatment and progressive 
patients require systemic treatment (Morgner et al 2007). 
Whereas patients with aggressive NHL are in general treated 
with R-CHOP, the signiﬁ  cance of rituximab in indolent 
disease has not been extensively studied. Single-agent treat-
ment for 4 weeks resulted in an ORR of 64% and a CR rate 
of  29% in gastric lymphoma in a phase II study in 35 patients 
with extranodal MZL. In a study focusing on primary gastric 
lymphoma, 26 patients showed an ORR of 77% (CR 46%), 
and with a median follow up of 33 months only 2 patients had 
experienced relapse (Martinelli et al 2005). In small series, Biologics: Targets & Therapy 2008:2(4) 628
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patients with ocular MZL have been treated with considerable 
success, but systematic evaluation is necessary (Nuckel et al 
2004; Zinzani et al 2005).
Localized extranodal MZL outside the stomach can 
sometimes be treated with curative intent by radiation 
therapy; however, other patients experience extensive disease 
and require systemic treatment, for which various agents are 
used. In this context, single-agent rituximab resulted in an 
ORR of 80% in patients with no initial gastric involvement 
and a median response duration of 10.5 months (Conconi 
et al 2003). Studies evaluating combined modality treatment 
are under way.
Splenic marginal zone lymphoma (SMZL)
SZML has been accepted recently as a separate entity 
(Harris et al 1994). It features distinct clinical signs such as 
predominant splenomegaly, lymphocytosis, and cytopenias. 
In contrast, lymphadenopathy is infrequently found on 
initial diagnosis. Some cases seem to be associated with 
hepatitis C virus infection (Mele et al 2003) and frequently 
autoimmune phenomena are found, which are often the main 
reason for treatment initiation. Most of the patients are treated 
with splenectomy and can experience long-term remissions 
(Thieblemont et al 2002; Thieblemont et al 2003). Data 
supporting a potential effect of rituximab are still scarce, 
except for anecdotical reports. A small study evaluated the 
value of ﬁ  rst-line rituximab treatment in 16 patients. In all 
patients normalization of spleen size was noted and the ORR 
was 100%, with a CR of 69%, and prolonged remissions were 
noted in some patients (Kalpadakis et al 2007).
With these limited data, rituximab could be considered as 
a therapeutic alternative in patients intolerant to splenectomy 
or chemotherapy on the basis of an individual treatment 
decision.
Hairy cell leukemia (HCL)
HCL is assigned to indolent NHL and is clinically char-
acterized by splenomegaly associated with pancytopenia. 
Diagnosis is made upon distinct cytological and immunophe-
notypic ﬁ  ndings. Patients may experience a disease course 
without requiring treatment, but most of the patients suffer 
from infections and progression of splenomegaly so that 
treatment has to be initiated.
Interferon-alpha, pentostatin, and cladribine have been 
introduced consecutively in the treatment of HCL, and the last 
named is now accepted as the standard of care (Golomb et al 
1987; Spiers et al 1987; Piro et al 1990; Grever et al 1995; 
Rai et al 1995). However, almost all patients harbor minimal 
residual disease and eventually relapse after treatment 
(Pileri et al 1994). In these, rituximab has been evaluated 
in small series, which gave heterogeneous results. A trial 
in 15 patients with relapsed disease resulted in an ORR of 
80% and a CR of 53%, in marked contrast to another series of 
24 patients in which only 26% of patients responded (Nieva 
et al 2003; Thomas et al 2003). Elimination of minimal 
residual disease after treatment with nucleoside analogues 
could be achieved with rituximab (Ravandi et al 2006), and 
current recommendations suggest using the antibody in case 
of cladribine and pentostatine failure (Lauria et al 2001; 
Golomb 2008).
Waldenström’s disease (WM)
WM is a distinct clinicopathological entity whose diagnostic 
criteria include presence of monoclonal IgM, bone marrow 
inﬁ  ltration with small lymphocytes with plasmacytoid/
plasma cell differentiation, and an intertrabecular inﬁ  ltra-
tion pattern (Owen et al 2003). Frequently symptoms such 
as fatigue, neuropathy, amyloid associated cardiomyopathy, 
or cytopenias due to bone marrow involvement are present 
during the disease course. Owing to the limited number 
of patients there are only few clinical trials, and results of 
studies in other lymphoma entities have been extrapolated 
for therapeutic decision making. Because all WM cells 
eventually express CD20, rituximab was explored and initial 
trials showed some efﬁ  cacy of the drug. Treon et al (2001) 
evaluated the single-agent activity in a series of 30 patients 
with relapsed disease, and with the criteria used in this 
trial an ORR of 60% was noted. Additional trials showed 
response rates of 44% and 52% (24.6% minor responses) 
(Dimopoulos et al 2002; Gertz et al 2004). Interestingly, a 
protracted response to rituximab was noted in a large pro-
portion of responding patients (Treon et al 2005). In some 
patients a paradoxical raise of IgM can be observed with 
initial rituximab treatment (ﬂ  are), which can result in the 
development of hyper-viscosity syndrome. Rituximab has 
now become one of the primary single-agent choices for 
ﬁ  rst-line treatment of  WM. Combination with chemotherapy 
was evaluated in small studies, and recently the results of 
a prospective phase II trial evaluating the combination of 
dexamethasone, cyclophosphamide, and rituximab in previ-
ously untreated patients were reported. Seventy-two patients 
were enrolled and 74% of them achieved CR or PR. Two-
year PFS was 67%, and was 80% in responding patients 
(Dimopoulos et al 2007). Furthermore, in the subgroup of 
patients enrolled in the study of the GLSG, patients ran-
domized to R-CHOP experienced a higher response rate Biologics: Targets & Therapy 2008:2(4) 629
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than patients treated with CHOP, which was translated into 
a signiﬁ  cant prolongation of PFS (Buske et al in press). 
Rituximab could be established as an active treatment for 
this disease entity.
Lymphoma of the central nervous system 
(CNS-lymphoma)
The treatment of primary CNS-lymphoma, almost uniformly 
of aggressive B-cell subtype, is still one of the major 
challenges in NHL. Whereas methotrexate is accepted as 
the therapeutic mainstay for ﬁ  rst-line treatment (Ferreri et al 
2003), curing relapsed disease is almost impossible. Although 
rituximab does not cross the blood-brain barrier physiologi-
cally, in neoplastic processes within the CNS the barrier might 
become permeable for monoclonal antibodies (Wong 2005). 
Therefore, rituximab could be a reasonable candidate drug to 
improve treatment results, and various therapeutic approaches 
have been evaluated. A small initial series reported on 3 out 
of 4 patients with primary CNS-lymphoma responding to 
intrathecal rituximab treatment (Schulz et al 2004). A phase I 
trial in patients with lymphomatous meningitis reported on 
6 out of 10 patients with cytological responses and reduc-
tion of tumor masses in 3 patients (Rubenstein et al 2007). 
However, survival of patients was poor. The combination of 
rituximab with temozolomide has attracted some attention 
in CNS-lymphoma treatment. In a small series of patients an 
ORR of 100% was observed. However, in a recently reported 
trial median PFS did not differ from single temozolomide 
treatment and an ORR of 53% was observed (Enting et al 
2004). In a retrospective study an ORR of 100% was reported 
for the combination of rituximab with a methotrexate based 
regimen (R-MTX) (Yamanaka et al 2008), but this approach 
requires additional supporting data. A recently published 
prospective trial reported on a combined modality treatment 
strategy including methotrexate-based chemotherapy (MVP), 
rituximab, and whole-brain irradiation and consolidation 
treatment with cytarabinoside in 30 untreated CNS-NHL 
patients (Shah et al 2007). An ORR of 93% to 5 cycles of 
R-MVP was observed. CR-rate was 44% at this time point 
and further improved after completing the entire treatment, 
and 2-year PFS was 57%. The beneﬁ  t of rituximab cannot 
easily be denominated in this treatment approach. However, 
CSF rituximab levels were 0.1%–4.4% of serum levels and 
therefore at least some activity can be assumed. Although 
these are stimulating data, in conclusion, no deﬁ  ned role of 
rituximab as single agent or as part of combination therapy for 
patients with primary CNS-lymphoma has been established 
at this stage and further clinical work is needed.
Multiple myeloma (MM)
Newer ﬁ  ndings have refuted the initially accepted CD20 
negativity of plasma cells (Gorschluter et al 2001). In a 
small proportion of patients with MM, CD20 positive plasma 
cells have been found; however, the expression pattern is 
frequently not uniform. In addition, CD20 expression may 
change during the disease course (Robillard et al 2003; 
Bergua et al 2008), and it may be worthwhile occasionally 
repeating diagnostic evaluation. The dual compartment 
theory of MM assumes that two different cell populations 
are present: besides the classical, terminally differentiated 
MM plasma cell, a smaller CD20 positive B-cell population 
is postulated, which is clonogenic and might be respon-
sible for myeloma initiation, progression, and maintenance 
(Chen and Epstein 1996; Rottenburger et al 1999; Pilarski 
et al 2000; Matsui et al 2004). If this is true, elimination of 
the precursor cell could prevent relapse after treatment for 
MM. Although the dual compartment theory is not generally 
accepted, clinical trials exploring rituximab have been initi-
ated. In small series, various responses have been observed 
in selected patients. Partial remissions are rare; however, 
a stabilization of paraprotein levels has been observed in 
50%–57% of patients for a period of up to 27 months (Treon 
et al 2002; Moreau et al 2007). So, although there is not yet 
a clearly established role of rituximab in the treatment of 
MM, future trials may help to elucidate its potential in this 
disease.
Summary and perspective
The introduction of rituximab for the treatment of NHL has 
been a milestone for patients affected with these diseases. 
A positive inﬂ  uence on results could be achieved in almost 
any randomized clinical trial, and even in population-based 
registries a lowering of lymphoma speciﬁ  c mortality could 
be noted. Therefore it can be concluded that rituximab, with 
only few exceptions, can today be generally accepted as a 
standard component of anti B-NHL therapies. Moreover, the 
successful implementation of an immunotherapy approach 
has triggered the development of a variety of other monoclo-
nal antibodies in lymphoma and unrelated tumor entities, and 
has at last helped to bring Paul Ehrlich’s vision to fruition.
Today, monotherapy, combination chemoimmunother-
apy, and maintenance strategies have been successfully used 
in large trials, especially of diffuse large B-cell lymphoma, 
follicular lymphoma, and mantle cell lymphoma, where ritux-
imab now is one of the key drugs for the treatment of these 
diseases. In rarer lymphoma entities only few randomized 
trials are available, but from these and from phase II trials Biologics: Targets & Therapy 2008:2(4) 630
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the use of the drug seems reasonable in MZL, WM, HCL, 
HIV-associated lymphomas with special precautions, and 
recently CLL. The role of rituximab in the treatment of MM 
remains to be answered. Although this rapidly driven devel-
opment has addressed so many subtypes of NHL, until now 
knowledge about optimal dosing and application schedules 
is still surprisingly scarce.
There are several other antibodies for the treatment of 
malignant lymphoma which are already established or in 
clinical development. Alemtuzumab, an anti-CD52 antibody, 
has been approved for the treatment of CLL, and radioim-
munoconjugates targeting CD20 are in use for patients with 
follicular and transformed lymphoma and also for other 
lymphoma subtypes. Several other CD20 antibodies are in 
clinical trials, and ofatumomab, especially, could be available 
shortly. Antibodies targeting CD19, CD20, CD22, in combi-
nation with a toxin, CD23, CD40, CD80, and HLA-DR are 
being evaluated in clinical trials, and their additional beneﬁ  t 
will be evaluated in coming years (DiJoseph et al 2004, 2006; 
Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 
2006). Although it seems unlikely now that these drugs will 
add as much beneﬁ  t as rituximab, they may help to further 
improve patient prognosis.
A variety of other new agents, eg, proteosome inhibitors, 
inhibitors of the mammalian target of rapamycine, histone 
deacytlase inhibitors, BH3 mimetics and many more, which 
will be of interest to evaluate for their potential to further 
improve the efﬁ  cacy of immunochemotherapy regimens. 
Current research focuses on the preclinical evaluation of 
potential partners for these kinds of therapeutic agents, and 
ﬁ  rst clinical trials are promising.
A systematic evaluation of all these newer agents, together 
with established agents such as cytotoxic agents and ritux-
imab, is indispensable to fully elucidate their potential and to 
guide the next generation of therapeutic combinations.
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